Physician
Prime Healthcare Foundation - Coshocton, LLC
Prime Healthcare Foundation - Coshocton, LLC was paid $13.32M by Medicaid between Jan 2018 and Dec 2024, across 181 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 13% of everything it billed.
33Billing provider infoPRIME HEALTHCARE FOUNDATION - COSHOCTON, LLC
COSHOCTON, OH 43812
COSHOCTON, OH 43812
33aNPI1013468172assigned 10/24/2016
33bProvider typeInternal Medicine Physician
28Total paid$13.32M
24GClaims392,953
24DCodes billed181
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Ohio
Rank by total paid#4 of 663
Median peer was paid$17K
This provider vs. median765×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,271 | $1.62M | |
| 2019 | 43,196 | $1.49M | |
| 2020 | 32,057 | $1.51M | |
| 2021 | 41,819 | $1.72M | |
| 2022 | 47,483 | $1.96M | |
| 2023 | 106,307 | $2.95M | |
| 2024incomplete | 71,820 | $2.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 21,388 | 18,257 | $1.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 19,113 | 17,639 | $1.69M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 12,428 | 10,529 | $1.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 15,209 | 13,811 | $1.43M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 34,640 | 28,858 | $1.41M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.3% | 29,292 | 25,805 | $1.10M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.0% | 4,576 | 3,595 | $1.06M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.2% | 4,813 | 4,306 | $429K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.8% | 5,019 | 4,609 | $374K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 1,238 | 1,028 | $238K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 2,974 | 764 | $214K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 917 | 712 | $211K |
169 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 960 | $207K |
| 80053 | Comprehensive metabolic panel | 1.5% | 16,713 | $201K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,450 | $120K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,251 | $114K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,879 | $102K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 998 | $97K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 11,687 | $82K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,926 | $60K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 412 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,855 | $47K |
| 87070 | <1% | 2,412 | $43K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,402 | $42K |
| 97161 | <1% | 520 | $40K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 963 | $40K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,332 | $38K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 346 | $35K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,741 | $29K |
| 87400 | <1% | 1,886 | $26K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,747 | $26K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 365 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,198 | $25K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 125 | $23K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 611 | $21K |
| 99223 | Prolong inpt eval add15 m | <1% | 584 | $21K |
| 84484 | <1% | 7,011 | $21K | |
| 73630 | <1% | 533 | $20K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 101 | $19K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,300 | $19K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,876 | $18K |
| 80061 | Lipid panel | <1% | 2,440 | $18K |
| 99406 | <1% | 598 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,100 | $16K |
| 87081 | <1% | 1,462 | $16K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,290 | $15K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,258 | $14K |
| G0378 | Hospital observation service, per hour | <1% | 299 | $14K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 157 | $13K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 130 | $13K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,613 | $13K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 93 | $12K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 255 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 765 | $11K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,880 | $11K |
| 73610 | <1% | 250 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 937 | $9K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 419 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,718 | $9K |
| 82607 | <1% | 477 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,812 | $8K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 262 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,596 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 20 | $6K |
| 81001 | <1% | 5,644 | $6K | |
| 81025 | <1% | 1,779 | $6K | |
| 73130 | <1% | 188 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 114 | $5K |
| 97113 | <1% | 114 | $5K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 188 | $5K |
| 85610 | <1% | 3,829 | $5K | |
| 83690 | <1% | 3,313 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 42 | $4K |
| 84439 | <1% | 332 | $4K | |
| 73030 | <1% | 169 | $4K | |
| 84702 | <1% | 824 | $4K | |
| 73562 | <1% | 83 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 53 | $3K |
| 87186 | <1% | 859 | $3K | |
| 83605 | <1% | 1,684 | $3K | |
| 83880 | <1% | 612 | $3K | |
| 83735 | <1% | 1,116 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 162 | $3K |
| 85379 | <1% | 949 | $3K | |
| 87807 | <1% | 793 | $3K | |
| 85730 | <1% | 2,784 | $3K | |
| 93971 | <1% | 32 | $3K | |
| 82728 | <1% | 184 | $2K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 166 | $2K |
| 99457 | <1% | 200 | $2K | |
| 83540 | <1% | 324 | $2K | |
| 81003 | <1% | 2,657 | $2K | |
| 85027 | <1% | 852 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 442 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 162 | $2K |
| 81002 | <1% | 495 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,278 | $2K |
| 73110 | <1% | 30 | $1K | |
| 82553 | <1% | 182 | $1K | |
| 99458 | <1% | 38 | $1K | |
| 90686 | <1% | 97 | $1K | |
| 80076 | <1% | 163 | $1K | |
| 74018 | <1% | 48 | $1K | |
| 86140 | <1% | 109 | $1K | |
| 99441 | <1% | 166 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 114 | $941.70 |
| G0008 | Administration of influenza virus vaccine | <1% | 128 | $922.13 |
| 94760 | <1% | 197 | $848.30 | |
| 96376 | <1% | 414 | $785.24 | |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 64 | $767.16 |
| 85652 | <1% | 269 | $761.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,999 | $749.58 |
| 99201 | <1% | 96 | $685.90 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 127 | $666.80 |
| 82550 | <1% | 554 | $643.84 | |
| 82948 | <1% | 642 | $642.85 | |
| 82746 | <1% | 48 | $591.00 | |
| 82150 | <1% | 380 | $571.66 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 25 | $520.14 |
| 83550 | <1% | 54 | $434.98 | |
| 86803 | <1% | 17 | $421.86 | |
| 82525 | <1% | 12 | $275.51 | |
| 73502 | <1% | 15 | $257.12 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 452 | $215.59 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 797 | $190.35 |
| 99454 | <1% | 70 | $188.36 | |
| 80320 | <1% | 49 | $185.76 | |
| 99442 | <1% | 13 | $181.65 | |
| 88142 | <1% | 15 | $181.14 | |
| 84630 | <1% | 12 | $175.35 | |
| 84703 | <1% | 67 | $109.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 224 | $105.22 |
| 84100 | <1% | 23 | $79.52 | |
| 99490 | Ccm add 20min | <1% | 25 | $74.61 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 20 | $66.88 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 424 | $45.76 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,734 | $29.88 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 894 | $23.42 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 63 | $21.60 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 617 | $18.56 |
| 36416 | <1% | 27 | $11.43 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 202 | $8.76 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 120 | $4.28 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 484 | $2.23 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 166 | $1.90 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 212 | $1.48 |
| J2704 | Injection, propofol, 10 mg | <1% | 944 | $1.17 |
| 3074F | <1% | 4,372 | $0.53 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 131 | $0.36 |
| 3078F | <1% | 3,432 | $0.34 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 692 | $0.18 |
| 3079F | <1% | 712 | $0.18 | |
| 91300 | <1% | 16 | $0.10 | |
| 3080F | <1% | 16 | $0.07 | |
| 3077F | <1% | 32 | $0.06 | |
| 3044F | <1% | 110 | $0.03 | |
| 3075F | <1% | 64 | $0.01 | |
| 3008F | <1% | 13,004 | $0.01 | |
| 1160F | 0% | 15,424 | $0.00 | |
| 4004F | 0% | 67 | $0.00 | |
| 3288F | 0% | 984 | $0.00 | |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 132 | $0.00 |
| G9577 | Patients prescribed opiates for longer than six weeks | 0% | 133 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 333 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 129 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 133 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 52 | $0.00 |
| G9561 | Patients prescribed opiates for longer than six weeks | 0% | 132 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 251 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 36 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 21 | $0.00 |
| 90461 | 0% | 14 | $0.00 | |
| 01992 | 0% | 25 | $0.00 | |
| 1126F | 0% | 2,930 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 51 | $0.00 |
| 1125F | 0% | 1,346 | $0.00 | |
| G9583 | Patients prescribed opiates for longer than six weeks | 0% | 130 | $0.00 |
| A9270 | Non-covered item or service | 0% | 202 | $0.00 |
| 1036F | 0% | 100 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 16 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.